Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise® in performance or availability. We are making better chemistry biologically.

Management

Image of John Melo
With Amyris since 2007

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Download Photo

Recent Stock Transactions by John Melo
Date Type Shares Traded Price Range
Apr 1, 2017 Disposition (Non Open Market) 37,580 0.52
Nov 1, 2016 Disposition (Non Open Market) 37,580 1.06
Jun 14, 2016 Sell 200,577 1.04
Jun 1, 2016 Disposition (Non Open Market) 53,238 0.54
May 16, 2016 Acquisition (Non Open Market) 425,000 n/a
Apr 1, 2016 Disposition (Non Open Market) 67,518 1.09
Nov 9, 2015 Acquisition (Non Open Market) 300,000 n/a
Jun 8, 2015 Acquisition (Non Open Market) 425,000 n/a
Jun 5, 2015 Automatic Sell 20,440 1.96
Jun 4, 2015 Automatic Sell 20,418 2.00
Jun 3, 2015 Automatic Sell 20,418 2.04
May 12, 2015 Automatic Sell 20,440 2.04
May 11, 2015 Automatic Sell 20,418 2.04
May 8, 2015 Automatic Sell 24,717 2.15
Apr 1, 2015 Disposition (Non Open Market) 73,781 2.45
May 15, 2014 Sell 172,186 3.02
May 5, 2014 Acquisition (Non Open Market) 300,000 n/a
Apr 1, 2014 Disposition (Non Open Market) 126,677 4.44
Jan 1, 2014 Disposition (Non Open Market) 3,363 4.71
Jun 3, 2013 Acquisition (Non Open Market) 239,000 n/a
May 24, 2013 Sell 24,402 2.85
Apr 1, 2013 Disposition (Non Open Market) 6,113 3.06
Jan 2, 2013 Disposition (Non Open Market) 3,364 3.20
Aug 31, 2012 Sell 553,730 3.70
Aug 31, 2012 Sell 115,000 3.70
Aug 31, 2012 Option Execute 553,730 0.28
Aug 31, 2012 Option Execute 115,000 0.28
May 15, 2012 Acquisition (Non Open Market) 3,273 1.53
Apr 9, 2012 Acquisition (Non Open Market) 250,000 n/a
Jan 3, 2012 Disposition (Non Open Market) 3,225 12.27
Oct 10, 2011 Automatic Sell 20,000 17.22
Oct 10, 2011 Option Execute 20,000 0.28
Aug 10, 2011 Automatic Sell 27,500 20.02 - 20.67
Aug 10, 2011 Option Execute 27,500 0.28
Aug 9, 2011 Automatic Sell 23,800 19.66 - 20.44
Aug 9, 2011 Option Execute 23,800 0.28
Aug 8, 2011 Automatic Sell 18,500 20.04 - 20.55
Aug 8, 2011 Option Execute 18,500 0.28
Jul 8, 2011 Automatic Sell 6,000 28.28
Jul 8, 2011 Option Execute 6,000 0.28
Jul 7, 2011 Automatic Sell 7,000 27.97
Jul 7, 2011 Option Execute 7,000 0.28
Jul 6, 2011 Automatic Sell 4,500 28.21
Jul 6, 2011 Option Execute 4,500 0.28
Jul 5, 2011 Automatic Sell 8,000 27.89
Jul 5, 2011 Option Execute 8,000 0.28
Jul 1, 2011 Automatic Sell 19,970 28.05
Jul 1, 2011 Option Execute 19,970 0.28
Jun 30, 2011 Automatic Sell 11,900 28.19
Jun 30, 2011 Option Execute 11,900 0.28

Kathleen “Kathy” Valiasek joined Amyris as Chief Financial Officer in January 2017. Her results-driven background includes specific areas of expertise in finance, strategic planning, debt and equity financing, business development, and mergers and acquisitions. Prior to joining Amyris, Valiasek was Founder and Chief Executive Officer of Lenox Group, Inc., a finance and strategic consulting firm where she worked closely with the senior management teams of fast-growing companies including start-ups, venture-backed and Fortune 500 companies.  She has deep experience across diverse industries including life sciences, tech, retail, telecommunications, and healthcare. Prior to her role at Lenox Group, she served in key venture capital, real estate development and accounting roles. Valiasek holds a Bachelor of Business Administration degree in accounting from the University of Massachusetts, Amherst.

Image of Christine Ofori

As Amyris Chief Human Resources Officer, Christine Ofori is responsible for leading and integrating all facets of Amyris’s HR goals, including people strategy and enhancement of company culture in order to deliver and enable business growth.  Christine brings many years of HR leadership experience to Amyris, including successful integration of people, technologies, processes and cultures.  Most recently, Christine served as Vice President of Human Resources at Amyris where she guided all aspects of employee development, staffing and business partnering.  Prior to that, she spent over eight years with Equinix, Inc. as Senior Director, Human Resources supporting the Americas Region.  Christine studied Business at the University of Minnesota.  

Download Photo

Image of Joel Cherry Ph.D.
With Amyris since 2008

Joel Cherry leads Amyris research and development, including various ongoing collaborations. Prior to joining Amyris, Dr. Cherry was Senior Director of bioenergy biotechnology at Novozymes. During his tenure at Novozymes, he was a member of the R&D management team specializing in protein engineering and directed evolution technologies. He was also principal investigator and director of the BioEnergy Project, an effort funded by the U.S. Department of Energy to reduce the cost of enzymes used in converting biomass to sugar. This work was awarded an R&D 100 Award, Scientific American Top 50 Award, and a Frost and Sullivan Emerging Technology Award. Dr. Cherry is an inventor on more than 20 issued patents, author of three book chapters and more than 30 scientific publications, and an invited speaker at numerous international conferences on biofuels. He received his B.A. from Carleton College in chemistry, a Ph. D. in biochemistry from the University of New Hampshire.

Download Photo

Recent Stock Transactions by Joel Cherry Ph.D.
Date Type Shares Traded Price Range
Apr 1, 2017 Disposition (Non Open Market) 11,248 0.52
Nov 1, 2016 Disposition (Non Open Market) 9,301 1.06
Jun 1, 2016 Disposition (Non Open Market) 13,779 0.54
May 16, 2016 Acquisition (Non Open Market) 200,000 n/a
Apr 1, 2016 Disposition (Non Open Market) 24,935 1.09
Nov 9, 2015 Acquisition (Non Open Market) 74,250 n/a
Jun 8, 2015 Acquisition (Non Open Market) 110,000 n/a
Apr 1, 2015 Disposition (Non Open Market) 32,135 2.45
May 5, 2014 Acquisition (Non Open Market) 92,000 n/a
Apr 1, 2014 Disposition (Non Open Market) 58,373 4.44
Jan 1, 2014 Disposition (Non Open Market) 1,462 4.71
Jun 3, 2013 Acquisition (Non Open Market) 111,000 n/a
Apr 1, 2013 Disposition (Non Open Market) 6,724 3.06
May 15, 2012 Acquisition (Non Open Market) 1,103 1.53
Apr 9, 2012 Acquisition (Non Open Market) 155,000 n/a
Jan 3, 2012 Disposition (Non Open Market) 1,402 12.27
Jan 3, 2012 Disposition (Non Open Market) 1,462 3.20
Sep 26, 2011 Automatic Sell 4,500 19.47
Sep 26, 2011 Option Execute 4,500 4.31
Aug 29, 2011 Automatic Sell 500 19.89
Aug 29, 2011 Option Execute 500 4.31
Aug 26, 2011 Automatic Sell 4,000 18.35
Aug 26, 2011 Option Execute 4,000 4.31
Aug 8, 2011 Automatic Sell 4,500 20.05
Aug 8, 2011 Option Execute 4,500 4.31
Jun 27, 2011 Automatic Sell 5,000 29.75 - 30.37
Jun 27, 2011 Option Execute 5,000 4.31
Jun 24, 2011 Automatic Sell 4,397 29.90
Jun 24, 2011 Option Execute 4,397 4.31
Jun 21, 2011 Automatic Sell 3,068 29.91
Jun 21, 2011 Option Execute 3,068 4.31
May 27, 2011 Automatic Sell 914 29.90
May 27, 2011 Option Execute 914 4.31
May 26, 2011 Automatic Sell 6,621 28.64 - 29.90
May 26, 2011 Option Execute 6,621 4.31
May 9, 2011 Automatic Sell 5,000 25.01
May 9, 2011 Option Execute 5,000 4.31
Apr 15, 2011 Acquisition (Non Open Market) 10,000 n/a
Mar 29, 2011 Automatic Sell 3,000 28.08
Mar 29, 2011 Option Execute 3,000 4.31
Mar 28, 2011 Automatic Sell 5,000 27.14
Mar 28, 2011 Option Execute 5,000 4.31
Image of Cynthia "Cindy" Bryant

Cindy Bryant leads Amyris's corporate development and collaborations efforts. She joined the company in June 2015 as Senior Vice President Corporate Development and Collaborations and, prior to joining Amyris, she served as Senior Director Marketing and Business Development for Novozymes (Denmark) where she developed and managed the company's global Household Care business. Bryant had P&L responsibility for this global business unit that represents approximately a third of Novozyme's overall business. Previously, her roles at Novozymes (USA) included Senior Director Global Biomass Business Development, where she was responsible for growing the company's global cellulosic ethanol business and as Global Marketing Manager – Biofuels, where she was responsible for strategy development, execution, and public relations. Before joining Novozymes, Bryant worked as Marketing Manager for Chevron Corporation's retail downstream business. She has also held product management and operational and engineering roles with other companies such as Assyst GmbH (Germany/USA) and Burlington Industries Inc. Bryant holds a Masters in Business Administration from University of California, Berkeley, as well as a Bachelor of Science degree in textile engineering from North Carolina State University.

Download Photo

Image of Caroline Hadfield

Caroline Hadfield joined Amyris in June 2015 as Senior Vice President, Personal Care, and leads the company's B2B and B2C sales initiatives for its consumer cosmetic products. Previously, Hadfield owned and operated an established retail consultancy practice specializing in the health, wellness and the personal care market sectors. Prior to that, she cofounded luxury spa interests in the United Kingdom and San Francisco where she developed branded spa products and also served as Global Product Director for Bodyshop International, where she was responsible for a complete range of globally sourced and regionally targeted products and contributed extensively to marketing strategy and packaging design. Before joining Bodyshop, Hadfield was Senior Vice President at Sephora (part of LVMH Group) and was part of the executive team that rolled out the Sephora concept across the U.S., opening 50 stores within just 18 months. Her experience also includes prior roles in merchandizing as SVP – General Merchandise Manager with Duty Free Shoppers (part of LVMH) and as Buying Controller with Burton Group (now Arcadia). Hadfield holds a Bachelor of Arts (Honours) degree in textiles and management from Leeds University and has completed a Senior Executive Program at Stanford University.

Download Photo

Jim Iacoponi joined Amyris in 2015 and is responsible for all farnesene and derivatives sales to industrial customers, across the fuels, lubricants, polymers, synthetic rubber, and solvents markets. Additionally, he leads the supply chain, regulatory and co-product teams for the company. Iacoponi has over three decades of diverse experience in the downstream energy business. Prior to joining Amyris he was Vice President of Operations for Propel Fuels, building California’s leading renewable fuel retail network, providing flex fuel and renewable diesel to consumers. Previously, he served at BP P.L.C. for 28 years where he held numerous leadership roles including in convenience retailing, petroleum refining, sales operations, strategy development, business restructuring, and supply chain management. Jim has extensive customer-facing background in B2B and B2C channels as well as in global specialty chemical sales. He led BP’s company-operated and dealer business (2,400 locations, 10,000 employees) east of the Rockies, and BP’s transition in the US to a franchisee-owned and operated business. He has held senior finance positions in manufacturing, and led BP’s planning, forecasting and performance management activity for its global retail business. He holds a Bachelor of Science in Civil Engineering from the University of Notre Dame and a Master of Science in Management from Purdue University.

Image of Charles Kraft
With Amyris since 2012

Chuck Kraft leads Amyris's global manufacturing and process development operations. Mr. Kraft has three decades of experience in specialty fermentation. Prior to joining Amyris, he was Vice President of Operations, and earlier Vice President of Engineering, at DuPont Tate and Lyle BioProducts, a joint venture producing 1, 3-propanediol (Bio-PDO™) via fermentation of plant-based sugars. Previously, for nearly two decades, he held a number of operational positions at Tate & Lyle's citric acid production facility in the United States. He holds MBA and B.S. Degrees from the University of Dayton, Ohio.

 

Download Photo

Stock transaction information provided by EDGAR Online. Amyris makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.